The European Medicines Evaluation Agency announced on Friday a review of the calcium channel blocker felodipine because of concerns about the original studies used to gain marketing authorization.
In a statement it said that its CPMP scientific committee had started a Community-wide review of five generic felodipine-containing medicinal products authorized in a number of Member States through the mutual recognition procedure.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!